Immunophenotype ofproducts. We employed immunophenotyping according to the gating strategy shown in panel A to characterize the cell products collected from healthy donor (HD) bone marrow (BM; n = 8), HD mobilized apheresis product (AP) obtained after G-CSF stimulation (n = 4), SCD BM pre-Plx (n = 2) and post-Plx (n = 3), and SCD AP obtained after Plx administration (n = 6). Bone marrow products are unselected and apheresis products are CD34⁺ selected (B).